Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care
  • CME

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: December 29, 2020 Expiration: December 28, 2021
Start Activity
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novartis Pharmaceuticals Corporation
Vinod Chandran, MBBS, MD, DM, PhD
person default
Alexis Ogdie, MD, MSCE

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the accumulating clinical study and real-world evidence regarding the efficacy and safety of IL-targeted biologics in patients with PsA who have had an inadequate response to conventional synthetic DMARDs
  • Describe the clinical results from recent studies that evaluated an interleukin blocker as initial therapy in patients with a new diagnosis of moderate to severe PsA

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Vinod Chandran, MBBS, MD, DM, PhD

Associate Professor
Consultant Rheumatologist
Division of Rheumatology
Department of Medicine
University of Toronto
University Health Network
Toronto, Canada

Vinod Chandran, MBBS, MD, DM, PhD, has disclosed that he has received funds for research support from AbbVie and Amgen and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB.
Alexis Ogdie, MD, MSCE

Associate Professor of Medicine and Epidemiology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Alexis Ogdie, MD, MSCE, has disclosed that she has received funds for research support from Amgen; consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Gilead Sciences, Lilly, Novartis, and Pfizer; and other financial or material support from Novartis and Pfizer.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatology specialists including physicians and other healthcare providers who care for patients with psoriasis.

Goal

The goal of this activity is to improve the knowledge and competence of learners to integrate early use of novel (eg, IL inhibitor) biologic treatment strategies in the management of patients with moderate to severe active PsA.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 29, 2020, through December 28, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Guidelines and Therapies
  • CME

Loading...
Vinod Chandran, MBBS, MD, DM, PhD
person default
Alexis Ogdie, MD, MSCE
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: December 29, 2020 Expiration: December 28, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.
PreviousNext

Related Content

Clinical Care Options (CCO) expert commentary on new data on IBD pathogenesis and management from the 2021 virtual Crohn’s & Colitis Congress

Anita Afzali, MD, MPH, FACG Released: March 5, 2021

Expert commentary on emerging treatments in IBD from the 2021 virtual Crohn’s & Colitis Congress, from Clinical Care Options (CCO)

Bruce E. Sands, MD, MS Released: March 1, 2021

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 8, 2021 Expired: January 7, 2022

Video Chapters


Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue